ACE and diabetic kidney disease: If these renoprotective effects are confirmed in clinical trials designed primarily to evaluate renal outcomes, SGLT2 inhibitors may become the standard of care for diabetic nephropathy together with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers.